Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of oral 5-aminolevulinic acid hydrochloride for photodynamic diagnosis in malignant glioma surgery
CTR20242088Phase 3Completed
- Sponsor
- Taizhou Fudan-Zhangjiang Pharmaceutical
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 5-aminolevulinic acid in malignant glioma, sponsored by Taizhou Fudan-Zhangjiang Pharmaceutical. Started Jun 2024; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
malignant glioma
Beyond the preview
Go deeper on CTR20242088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242088.